Home » Stocks » Edesa Biotech

Edesa Biotech, Inc. (EDSA)

Stock Price: $7.24 USD 0.43 (6.31%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $7.05 -0.19 (-2.62%) Aug 13, 7:40 PM

Stock Price Chart

Key Info

Market Cap 64.14M
Revenue (ttm) 766,143
Net Income (ttm) -5.27M
Shares Out 8.86M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $7.24
Previous Close $6.81
Change ($) 0.43
Change (%) 6.31%
Day's Open 6.80
Day's Range 6.80 - 7.39
Day's Volume 171,512
52-Week Range 1.58 - 19.10

More Stats

Market Cap 64.14M
Enterprise Value 58.68M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 8.86M
Float 2.71M
EPS (basic) -0.59
EPS (diluted) -0.73
FCF / Share -0.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 74,395
Short Ratio 0.03
Short % of Float 1.93%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 83.72
PB Ratio 9.69
Revenue 766,143
Operating Income -5.36M
Net Income -5.27M
Free Cash Flow -4.58M
Net Cash 5.46M
Net Cash / Share 0.62
Gross Margin 53.88%
Operating Margin -699.79%
Profit Margin -713.30%
FCF Margin -598.07%
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $7.24
Target: 16.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth--82.05%67.62%103.88%-31.78%90.69%-58.97%-
Gross Profit--0.310.14-0.08-0.39-0.06-0.25-0.31
Operating Income-1.62-5.22-4.91-4.34-5.72-3.85-6.55-4.83
Net Income-1.87-5.03-5.03-2.84-8.44-14.50-5.53-3.60
Shares Outstanding3.
Earnings Per Share-0.47-20.64-23.94-15.12-46.62-118.02-54.60-37.80
Operating Cash Flow-1.29-4.70-4.51-4.41-4.27-2.80-3.95-2.62
Capital Expenditures-0.01-0.30-0.40-0.27-0.28-0.01-0.08-0.31
Free Cash Flow-1.30-5.00-4.91-4.69-4.54-2.81-4.03-2.93
Cash & Equivalents3.376.5711.418.970.007.861.004.15
Net Cash / Debt3.376.5711.418.970.007.861.004.15
Book Value3.217.4012.318.01--2.200.853.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Edesa Biotech, Inc.
Country Canada
Employees 10
CEO Pardeep Nijhawan

Stock Information

Ticker Symbol EDSA
Stock Exchange NASDAQ
Unique Identifier NASDAQ: EDSA


Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. Edesa Biotech, Inc. has a collaborative research project with the National Research Council of Canada to develop novel immunotherapies for vitiligo, as well as other indications; and Light Chain Bioscience for the development and commercialization of two Phase 2-ready biologic drug candidates for various therapeutic, prophylactic, and diagnostic applications. The company was founded in 2015 and is headquartered in Markham, Canada.